RIGAKU
9.5.2024 16:01:35 CEST | Business Wire | Press release
Rigaku Corporation, a Rigaku Holdings Group company and Rigaku global solution partner in X-ray analytical equipment (head office: Akishima, Tokyo; president and representative director: Jun Kawakami; hereinafter “Rigaku”), has completed analysis of particles from 101955 Bennu, a near-Earth carbonaceous asteroid classified as a type B. The analysis was performed using ZSX Primus IV, a wavelength dispersive X-ray fluorescence spectrometer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508939191/en/
ZSX Primus IV (Photo: Business Wire)
The particles from Bennu are a sample obtained by OSIRIS-Rex, a spacecraft of the United States National Aeronautics and Space Administration (NASA). This analysis constitutes the second time Rigaku has been tasked with conducting analysis related to Bennu. On the first occasion, in December 2023, Rigaku measured water and carbon content in a sample from the carbonaceous asteroid using thermoanalysis.
The X-ray fluorescence spectrometry was conducted by the Rigaku Application Laboratory XRF Analytical Group in the presence of Professor Hisayoshi Yurimoto of the Faculty of Science, Hokkaido University, who directed the chemical analysis of samples brought back from the asteroid Ryugu by the Hayabusa 2 spacecraft.
The purpose of the analysis was to ascertain the content of major and trace elements including carbon and oxygen in sample. In the current measurements, quantitative analysis was performed on 26 elements Results of thermoanalysis and X-ray spectrometry were combined to learn about the history of Bennu and its similarities and differences with Ryugu.
The analysis of Bennu is now proceeding by worldwide project teams. A unique feature of the work of the Japan team, under the direction of Professor Yurimoto, is the application of thermoanalysis using thermogravimetry along with mass spectrometry and X-ray spectrometry using a wavelength dispersive X-ray fluorescence spectrometer.
One advantage of the Rigaku approach to thermoanalysis is that quantitative-analytical equipment is used in tandem, enabling Rigaku to separate and measure each element and type of molecule, with the result that unprecedented data can be obtained. Moreover, X-ray fluorescence spectrometry plays an exceptionally vital role: As the research method shifts toward inductively coupled plasma mass spectrometry (ICP-MS), X-ray fluorescence spectrometry can analyze major components such as carbon, oxygen, silicon and sulfur that are difficult to analyze using ICP-MS.
Professor Yurimoto commented: “The performance of the equipment is obviously vital, but in the end, what makes the difference is people. When conducting analysis on the leading edge of the field, the question of who does the analysis is paramount. I asked Rigaku to perform the analysis because this company brings to the table not only outstanding equipment but also superb engineers.”
Rigaku will continue to pursue close partnership with academia, contributing to the development of society through the advance of science and technology.
Related information
-
Press release regarding thermoanalysis conducted in December 2023
URL: https://rigaku.com/about/news-and-press-releases/rigaku-analyzes-samples-from-nasa?hsLang=en
Results of Rigaku’s Participation in the Initial Analysis Project of Ryugu Sample
In June 2019, Rigaku took part in the Ryugu project as a joint research partner. In 2021, the content percentages of elements in the sample from Ryugu were determined using ZSX Primus IV, a wavelength dispersive X-ray fluorescence (WDXRF) spectrometer. Measurements using TG-DTA/GC‐MS determined that the moisture content of the sample from Ryugu differed from that found in meteorites of carbonaceous chondrite, which are thought to reflect the mix of elements in the primordial solar system. These data now serve as the basic data from the Ryugu sample that research groups around the world are using to conduct a wide range of analyses.
Rigaku’s analytical results are cited in a paper by the chemical analysis team (led by Prof. Yurimoto) of the initial analysis team of the Hayabusa 2 mission, and are published in Science, a US-based scientific journal.
About The Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including in its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku.com (As of November 30, 2023)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508939191/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release
Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release
Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
